COMP <GO>
BIIB vs MRK // EV/EBITDA & P/E VALUATION
Biogen Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BIIB 5
— MRK 9
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
valuation
22.3x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 74.80% | +0.90 | BIIB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | 20.70% | -14.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 22.3x | 15.3x | +7.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | 3.42% | +2.14 | BIIB | /fcf-yield <GO> |
| Operating Margin | 15.90% | 34.30% | -18.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 28.10% | -15.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 1.30% | +0.90 | BIIB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 5.19 | -1.49 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 56.9 | +9.79 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.92 | +0.18 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 18.4x | +8.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.90B | $361.02B | -$324.12B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | MRK REV | BIIB GROSS % | MRK GROSS % | BIIB FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $65.01B | 75.7% | 74.8% | $2.05B | $12.36B |
| FY 2024 | $9.68B | $64.17B | 76.1% | 76.3% | $2.72B | $18.10B |
| FY 2023 | $9.84B | $60.12B | 44.0% | 44.0% | $1.10B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
MRK // BETA 0.92